Moreover, we identified trametinib as the most potent MEK inhibitor for MPNST and demonstrated that the reduced reactivation of the MAPK pathway and activation of the parallel pathways contributed to better efficacy. Here, MAP2K7 is linked to malignant peripheral nerve sheath tumor.